Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC

Martin Reck, MD, PhD, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer (NSCLC).

Findings from the study suggest that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) plus 2 cycles of platinum-doublet chemotherapy ​should be considered an option for this patient population.

However, it is an intensive regimen, says Reck. Moreover, treatment-emergent adverse effects (AEs) were observed more frequently with the experimental regimen compared with chemotherapy alone.

Treatment-related deaths occurred in 2% of patients in both arms.

Notably, the incidence of chemotherapy-related AEs including hematologic AEs was lower in the combination arm ​as patients received 2 ​cycles ​of chemotherapy versus 4, Reck concludes.

Related Videos
Jorge E. Cortes, MD
R. Lor Randall, MD, FACS
Lisa A. Carey MD, ScM, FASCO
Gregory Vidal, MD, PhD
Joshua Hill, MD, MS
Gary K. Schwartz, MD
Maya Khalil, MD, assistant professor of medicine, Division of Hematology and Oncology, the University of Alabama at Birmingham (UAB), oncologist, O’Neal Comprehensive Cancer Center, UAB Medicine
Jeffery Zonder, MD
Jeffery Zonder, MD
Julie Renee Brahmer, MD
Related Content